House committee plans to examine FDA's drug-safety efforts

03/4/2010 | Reuters

The House Energy and Commerce Committee scheduled a hearing Wednesday to look into the FDA's drug-safety efforts amid criticism that the agency is slow to respond to reports of adverse reactions to approved treatments. Deputy FDA Commissioner Joshua Sharfstein will appear before a health subcommittee as part of the inquiry.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park